Evidence mapPaperPMID 42219444Full record

ArticleApplied biochemistry and biotechnology2026

Dual-functional Green Tea Polyphenol loaded Chitosan Nanoparticles for Eradication of Uropathogenic Biofilm and Induction of Apoptotic Pathways in Prostate Cancer Cells.

Leena S Alqahtani

Abstract read
PubMed Publisher
In one paragraph

Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Leena S AlqahtaniDepartment of Biological Sciences, College of Science, University of Jeddah, Jeddah, 23445, Saudi Arabia. lsalqahtani@uj.edu.sa.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this work, chitosan nanoparticles (CsNPs) loaded with crude green tea extract (CGTE) at three concentrations (1.5, 3, and 6%) are designed to eradicate harmful microbes and eliminate prostate cancer cells successfully. The extraction of bioactive compounds in CGTE was conducted. A phytochemical identification confirmed that CGTE was rich in polyphenols and flavonoids, predominantly quercetin derivatives. Furthermore, the characterization of the prepared materials indicated that CGTE was successfully loaded onto CsNPs. The TEM results showed that CsNPs and the loaded CsNPs with CGTE were spherical, with their size increasing from around 297 nm to 353 nm after loading the CGTE. Among the studied formulations, results indicated that 6CGTE loaded CsNPs showed the strongest antimicrobial, antibiofilm, and anticancer activities. Likewise, the formulation induced significant cytotoxicity and apoptosis in PC-3 prostate cancer cells, as evidenced by morphological shrinkage, Annexin V-positive populations, and cell-cycle arrest. The cancer therapy of PC-3 prostate increased Bax levels and decreased Bcl-2 levels. ELISA and qRT-PCR tests revealed the significant downregulation of inflammatory mediators (IL-6 and TNF-α). In addition, western blot analysis confirmed the highest p53 levels and activated cleaved caspase-3. Consequently, the the prepared CGTE loaded CsNPs is a promising and beneficial approach for treating prostate cancer and preventing the bioburden of uropathogenic microbes. The results concluded that the prepared nanoplatform has great potential for biomedical and pharmaceutical applications as a localized nano-delivery system for integrated antimicrobial and anticancer therapy.

Indexed as

Antibiofilm activityChitosan-based nanoparticlesGreen tea polyphenolsMitochondrial apoptosis pathway (Bax/Bcl-2 axis)Prostate cancer (PC-3 cell line)

Identifiers

PMID42219444

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.